Poplin E, Fleming T, MacDonald J S, Eisenberg P, Fisher R I, Conrad M E
Wayne State University Medical Center, Detroit, MI.
Invest New Drugs. 1993 Feb;11(1):47-51. doi: 10.1007/BF00873910.
Amonafide, a synthetic benzisoquinolinedione, was evaluated for treatment of squamous esophageal cancer. Eleven men and 5 women were eligible with a median performance status of 1 and median age of 63 years. Six had no prior treatment. All patients had measurable disease. Therapy consisted of amonafide 300 mg/m2d days 1-5 every 21 days. Thirty-five courses of therapy were delivered. The median number of courses received was two. Sixteen patients are evaluable for toxicity. Thirteen are evaluable for response. Toxicity was severe. Seven patients were hospitalized for toxicity. Six patients had grade IV granulocytopenia; two, grade IV thrombocytopenia. Angioedema developed in one patient; severe exfoliative dermatitis in another. A single partial response, with the decrease in size a supraclavicular node, was noted in a previously untreated patient. Amonafide, in this dose and schedule, is associated with occasionally severe toxicity precluding its likely use in squamous cell esophageal carcinoma.
氨萘非特是一种合成的苯并异喹啉二酮，对其治疗食管鳞状细胞癌的效果进行了评估。11名男性和5名女性符合条件，中位体能状态为1，中位年龄为63岁。6名患者此前未接受过治疗。所有患者均有可测量的病灶。治疗方案为氨萘非特300mg/m²，第1 - 5天给药，每21天为一个疗程。共进行了35个疗程的治疗。接受疗程的中位数为两个。16名患者可评估毒性，13名可评估疗效。毒性严重。7名患者因毒性住院。6名患者出现IV级粒细胞减少；2名患者出现IV级血小板减少。1名患者发生血管性水肿；另1名患者出现严重剥脱性皮炎。在1名此前未接受过治疗的患者中观察到1例部分缓解，表现为锁骨上淋巴结缩小。该剂量和疗程的氨萘非特伴有偶尔出现的严重毒性，使其不太可能用于食管鳞状细胞癌的治疗。
